CLINICAL COMPARISON OF FIRST-LINE PLATIN CHEMOTHERAPY REGIMENS IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) USING GERMAN REGISTRY DATA

被引：3
|
作者：
Haas, J. S. [1 ]
Meise, D. [1 ]
Ogbonnaya, A. [2 ]
Braun, S. [1 ]
Eaddy, M. [3 ]
Daessler, K. [4 ]
Sandner, R. [5 ]
Binninger, A. [6 ]
Jaenicke, M. [6 ]
Chiabudini, M. [6 ]
Marschner, N. [7 ]
机构：
[1] Xcenda GmbH, Hannover, Germany
[2] Xcenda LLC, Sci Consulting, Palm Harbor, FL USA
[3] Xcenda LLC, Palm Harbor, FL USA
[4] Onkol Schwerpunktpraxis, Freital, Germany
[5] Gemeinschaftspraxis Dr Prenninger & Dr Sandner, Passau, Germany
[6] iOMEDICO AG, Freiburg, Germany
[7] Praxis Interdisziplinare Onkol & Hamatol, Freiburg, Germany
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.112
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN30
引用
收藏
页码：A416 / A417
页数：2
相关论文
共 50 条
  • [1] EVALUATION OF SURVIVAL OUTCOMES IN SELECT FIRST-LINE TREATMENT REGIMENS FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS
    Bhor, M.
    Winfree, K. B.
    Sail, K.
    Zagar, A.
    Pohl, G.
    Dhanda, R.
    VALUE IN HEALTH, 2013, 16 (03) : A1 - A1
  • [2] First-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) in China in the era of precision medicine
    Zhang, X.
    Zhou, Q.
    Song, Y.
    Chen, G. Y.
    Zhong, D. S.
    Yu, Z.
    Yu, P.
    Zhang, Y. P.
    Chen, J. H.
    Hu, Y.
    Feng, G. S.
    Song, X.
    Shi, Q.
    Yang, L. L.
    Zhang, P. H.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy
    Ahn, Hee Kyung
    Kim, Young Saing
    Kim, Eun Young
    Kyung, Sun Young
    Kang, Shin Myung
    Cho, Eun Kyung
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S910 - S911
  • [4] First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
    Andric, Z. G.
    Galffy, G.
    Cobo Dols, M.
    Szima, B.
    Stojanovic, G.
    Petrovic, M. D.
    Felip Font, E.
    Vicente Baz, D.
    Ponce Aix, S.
    Juan-Vidal, O.
    Tehenes, S.
    Szalai, Z.
    Losonczy, G.
    Calles Blanco, A.
    Bernabe, R.
    Duecker, K.
    Zhou, D.
    Schroeder, A.
    Guezel, G.
    Ciardiello, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S753 - S754
  • [5] THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wielage, R. C.
    Muehlenbein, C. E.
    Liepa, A. M.
    Babineaux, S. M.
    Klein, R. W.
    Schwartzberg, L. S.
    VALUE IN HEALTH, 2009, 12 (03) : A39 - A39
  • [6] First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous KRAS wild type (WT) non-small cell lung cancer (NSCLC)
    Mekhail, Tarek
    Waterhouse, David Michael
    Hadley, Terence J.
    Webb, Charles D.
    Burris, Howard A.
    Hainsworth, John D.
    Greco, F. Anthony
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Associations between biomarkers and outcomes of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Gronberg, B. H.
    Lund-Iversen, M.
    Strom, E. H.
    Brustugun, O. T.
    Scott, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Bevacizumab in combination with first-line metastatic chemotherapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): Results from the cohort study EOLE.
    Chouaid, Christos
    Schott, Roland
    Falchero, Lionel
    Bonnetain, Franck
    Neaume, Julien
    Bennouna, Jaafar
    Tagieva, Naila
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Economics of first-line treatment with tislelizumab in patients with nonsquamous non-small cell lung cancer
    Wang, Lin
    Liu, Ting
    Lin, Xihan
    Zhang, Yu
    Shi, Luwen
    You, Ruxu
    Liu, Jinyu
    IMMUNOTHERAPY, 2024, 16 (20-22) : 1217 - 1226
  • [10] EFFECTIVENESS OF FIRST-LINE PEMETREXED PLUS PLATINUM FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Brandao, M. D. R. A.
    Luis, M. S.
    Amaral, N. C.
    Cassiano Neves, M.
    Camacho, C.
    Rodrigues, A. C.
    Pousa, I.
    Oliveira, J.
    Azevedo, I.
    ANNALS OF ONCOLOGY, 2015, 26
12345